First Wave BioPharma (FWBI) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free FWBI Stock Alerts $2.96 +0.13 (+4.59%) (As of 05/16/2024 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 10:40 AM | finance.yahoo.comEntero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) ConferenceMay 16, 2024 | finance.yahoo.comFirst Wave BioPharma Changes Name to Entero TherapeuticsMay 15, 2024 | investorplace.comFWBI Stock Earnings: First Wave BioPharma Beats EPS for Q1 2024May 15, 2024 | americanbankingnews.comFirst Wave BioPharma (NASDAQ:FWBI) Shares Down 0.3% May 10, 2024 | globenewswire.comFirst Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketMay 9, 2024 | globenewswire.comFirst Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness MonthApril 24, 2024 | globenewswire.comFirst Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsApril 17, 2024 | finance.yahoo.comFirst Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseApril 15, 2024 | globenewswire.comFirst Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceApril 5, 2024 | investing.comFirst wave BioPharma CEO sells shares to cover tax obligationsMarch 21, 2024 | investing.comFirst wave BioPharma CFO sells shares worth over $5,500March 21, 2024 | investing.comFirst wave BioPharma CEO sells shares worth over $9,000March 18, 2024 | globenewswire.comFirst Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferenceMarch 14, 2024 | investorplace.comWhy Is First Wave BioPharma (FWBI) Stock Up Today?March 14, 2024 | msn.comFirst Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac DiseaseMarch 14, 2024 | globenewswire.comFirst Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical PipelineMarch 5, 2024 | finance.yahoo.comFirst Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth ConferenceMarch 5, 2024 | globenewswire.comFirst Wave BioPharma to Participate In ‘Fireside Chat' at the 36th Annual Roth ConferenceMarch 4, 2024 | marketwatch.comFirst Wave BioPharma Shares Drop 25% After Direct Offering PricesMarch 4, 2024 | msn.comFirst Wave Biopharma to raise about $4M of proceeds in direct offeringMarch 4, 2024 | finance.yahoo.comFirst Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct OfferingFebruary 13, 2024 | finance.yahoo.comFirst Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024January 23, 2024 | finance.yahoo.comFirst Wave BioPharma to Present at the DealFlow MicroCap ConferenceJanuary 22, 2024 | benzinga.comThis BioPharma Could Be First To Market With Its Celiac Therapy – Phase 3 Clinical Trials To Commence In 2024January 8, 2024 | msn.comFirst Wave BioPharma files to sell 1.76M for holdersJanuary 6, 2024 | msn.comFirst Wave expecting "significant" investments if ImmunogenX deal closesJanuary 4, 2024 | finance.yahoo.comFirst Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024January 3, 2024 | msn.comWhat's Going On With First Wave BioPharma Stock?January 3, 2024 | marketbeat.comTrading was temporarily halted for "FWBI" at 09:01 AM with a stated reason of "LULD pause."January 3, 2024 | realmoney.thestreet.comFirst Wave BioPharma price target set at $40 at Roth MKMJanuary 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for First Wave BioPharma Amid Strategic Focus on Celiac TreatmentDecember 28, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 12:12 PM with a stated reason of "LULD pause."December 28, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 12:12 PM with a stated reason of "LULD pause."December 27, 2023 | markets.businessinsider.comCrude Oil Falls Over 1%; First Wave BioPharma Shares Spike HigherDecember 27, 2023 | msn.comWhy First Wave BioPharma Shares Are Skyrocketing TodayDecember 27, 2023 | finance.yahoo.comFirst Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds PricedDecember 27, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 12:12 PM with a stated reason of "LULD pause."December 27, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 11:12 AM with a stated reason of "LULD pause."December 27, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 09:12 AM with a stated reason of "LULD pause."December 27, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 09:12 AM with a stated reason of "LULD pause."December 27, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 09:12 AM with a stated reason of "LULD pause."December 27, 2023 | markets.businessinsider.comFirst Wave BioPharma To Sell Niclosamide Program To Undisclosed Biopharmaceutical CompanyDecember 27, 2023 | finance.yahoo.comFirst Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD ProgramDecember 20, 2023 | marketbeat.comTrading was temporarily halted for "FWBI" at 02:12 PM with a stated reason of "LULD pause." Trading set to resume at 02:12 PM. December 20, 2023 | investorplace.comFWBI Stock Earnings: First Wave BioPharma Beats EPS for Q3 2023December 20, 2023 | investorplace.comFWBI Stock Earnings: First Wave BioPharma Reported Results for Q1 2023December 18, 2023 | finance.yahoo.comUPDATED: First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused PipelineDecember 18, 2023 | markets.businessinsider.comFirst Wave BioPharma To Acquire ImmunogenX In All-stock TransactionDecember 18, 2023 | msn.comFirst Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused PipelineDecember 18, 2023 | finance.yahoo.comFirst Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company Get First Wave BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FWBI and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. FWBI Media Mentions By Week FWBI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FWBI News Sentiment▼1.190.42▲Average Medical News Sentiment FWBI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FWBI Articles This Week▼51▲FWBI Articles Average Week Get First Wave BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FWBI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XBIO News ENVB News LIXT News KA News PCSA News ADIL News LIPO News HOTH News HILS News AIMD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FWBI) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold4 Cryptos BETTER than BitcoinTrue Market InsidersDoes this make you sick?Allegiance GoldBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist My Default Watchlist Adding First Wave BioPharma, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
